Nearly 3 months after the Swedish government first arrested leading oncopeptide clinical officer Jakob Lindberg, they shut down their research, the biotech said.
Lindberg, who was previously CEO of Oncopeptides, was investigated for allegedly passing internal data to someone outside the company in October 2021.
But according to a press release from Oncopeptides, the Swedish Economic Crime Authority has now said “that there is no longer any explanation as to why to complete the initial investigation because ‘the available investigative curtain [does not] appear that the user or users suspected any crime.
Unlock this story right away and sign up for over 170,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
We live in a new era of healthcare that advances and impacts patient outcomes and experiences. We have noticed a remarkable speed of transformative innovation, implemented studies, and complex clinical progression over the past decade.
Despite this great progress, there is still much work to be done and patients are counting on us, now more than ever, to continue this momentum. challenging diseases, adding those that today have few or no effective remedies.
As a number of gene treatment startups aim to create remedies without the inevitable back and forth of an AAV virus, and several gene-editing biotechnologies seek to do the same, the said venture is coming to an end.
Summation Bio, subsidized through at least $24 million in Series A funding, is “shutting down operations” next month, according to an update to a worker’s LinkedIn profile. (According to his LinkedIn profile, one worker said the company raised $60 million in the round. )Another worker visited the networking site last week to say the cases were “second to none” and noted that “despite all efforts and error-free execution, the science, this time, was elusive. “
Unlock this story right away and sign up for over 170,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Amylyx Pharmaceuticals’ ALS drug appears to be following a more complicated path in the EU than in the US. USA and Canada.
Biotech announced Tuesday morning that the bloc’s drug review committee, known as CHMP, is expected to have a “negative opinion” and oppose approving the drug next month. If this negative opinion materializes, Amylyx hopes to appeal as part of a “formal review. “”, according to a corporate press release.
Unlock this story right away and sign up for over 170,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Rain Oncology will lay off 65% of its workers, prevent patient enrollment in a group trial and forgo examining its only asset after a phase III failure last week.
The Newark, California-based biotech had about 70 workers at the time of the announcement last week, meaning 40 to 50 workers will be affected by the layoffs, CEO and co-founder Avanish Vellanki said in an email to Endpoints News. That includes Chief Medical Officer Richard Bryce, who will hand over his duties to Robert Doebele, Rain’s co-founder, president and chief clinical officer, the biotech said in a news release Tuesday.
Unlock this story right away and sign up for over 170,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
While one of its main bets on multiple sclerosis is stuck at a one-year partial clinical suspension, Sanofi has new medium-term insights into another investigational MS remedy that the company says will lay the groundwork for pivotal trials next year.
On Wednesday, the French pharmaceutical company said its experimental drug, frexalimab, was better than placebo at reducing certain types of brain damage, as seen in an MRI at week 12. The study included another 129 people with relapsing sclerosis.
Unlock this story right away and sign up for over 170,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
The FDA imposed a clinical suspension on PepGen’s IND for a drug for myotonic dystrophy 1 (T1DM), halting the company’s plans to introduce a momentary neuromuscular program into the clinic.
PepGen elaborated on what concerns it, saying only that the FDA will provide an official letter within 30 days stating the reasons for the suspension.
Originating from the University of Oxford and supported through RA Capital, PepGen specialises in oligonucleotides (short strands of artificial DNA or RNA molecules) that are delivered with special peptides that enter cells. By conjugating peptides with oligonucleotides, biotechnology promises the absorption and activity of the resulting therapy. .
Unlock this item and others by subscribing to one of our paid plans.
A week after confirming Tang Capital’s Concentra Biosciences is offering to buy Atea Pharmaceuticals, the Boston-based biotech said its board rejected the unsolicited offer, which they said “basically undervalues Atea. “
Antiviral biotech, which has struggled to cross the finish line on Covid-19 and has reworked its priorities in recent quarters, said its board “unanimously concluded” that Concentra’s proposal “is not in the most productive interest of Atea or its shareholders. “The Board worked with outside financial and legal advisors to revise the $5. 75 monetary proposal consistent with Concentra’s constant percentage, which also included rights to 80% of the net proceeds from the sale through the buyer or license of Atea’s assets.
Unlock this story right away and sign up for over 170,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Alnylam once accused Pfizer and Moderna of infringing patents on its lipid nanoparticle technology.
In two lawsuits filed Friday, Alnylam alleged that Pfizer and Moderna profited from the generation of lipid particles he invented more than a decade ago. mobile, they unpack essential commands for the construction of mRNA proteins to create, for example, spike proteins to prepare the immune formula against Covid-19.
Unlock this story right away and sign up for over 170,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Eli Lilly will pay $13. 5 million and continue to cap insulin rates at $35 per month for the next four years as part of what plaintiffs have called an “icebreaker” elegance deal for a multi-year lawsuit worth of drugs.
Insulin users filed lawsuits against Eli Lilly, Novo Nordisk and Sanofi in 2017, accusing the drugmakers of “artificial and fraudulent inflation” of their insulin costs in the United States. list of costs “in the best harmony” through more than 150% over a five-year period.
Unlock this story right away and sign up for over 170,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
© Endpoints 2023 News
We will email you a link to set a new password. Please note that this link is for single use and is valid for 24 hours.